Compare Biocon with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs CIPLA - Comparison Results

BIOCON      Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON CIPLA BIOCON /
CIPLA
 
P/E (TTM) x 31.3 32.0 98.0% View Chart
P/BV x 3.7 4.5 82.6% View Chart
Dividend Yield % 0.3 0.5 58.2%  

Financials

 BIOCON    CIPLA
EQUITY SHARE DATA
    BIOCON
Mar-19
CIPLA
Mar-20
BIOCON /
CIPLA
5-Yr Chart
Click to enlarge
High Rs707586 120.8%   
Low Rs554357 155.2%   
Sales per share (Unadj.) Rs91.9207.0 44.4%  
Earnings per share (Unadj.) Rs16.718.6 89.9%  
Cash flow per share (Unadj.) Rs24.233.2 72.9%  
Dividends per share (Unadj.) Rs1.004.00 25.0%  
Dividend yield (eoy) %0.20.8 18.7%  
Book value per share (Unadj.) Rs101.6195.5 52.0%  
Shares outstanding (eoy) m600.00806.35 74.4%   
Bonus/Rights/Conversions -ESOS-  
Price / Sales ratio x6.92.3 301.5%   
Avg P/E ratio x37.725.3 148.9%  
P/CF ratio (eoy) x26.114.2 183.6%  
Price / Book Value ratio x6.22.4 257.4%  
Dividend payout %6.021.5 27.8%   
Avg Mkt Cap Rs m378,330379,912 99.6%   
No. of employees `0006.125.8 23.7%   
Total wages/salary Rs m11,65330,270 38.5%   
Avg. sales/employee Rs Th8,994.36,459.6 139.2%   
Avg. wages/employee Rs Th1,900.71,171.2 162.3%   
Avg. net profit/employee Rs Th1,635.3580.2 281.9%   
INCOME DATA
Net Sales Rs m55,144166,949 33.0%  
Other income Rs m1,4443,442 42.0%   
Total revenues Rs m56,588170,391 33.2%   
Gross profit Rs m15,88332,060 49.5%  
Depreciation Rs m4,47811,747 38.1%   
Interest Rs m7091,974 35.9%   
Profit before tax Rs m12,14021,782 55.7%   
Minority Interest Rs m9-475 -1.9%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,1236,312 33.6%   
Profit after tax Rs m10,02614,995 66.9%  
Gross profit margin %28.819.2 150.0%  
Effective tax rate %17.529.0 60.3%   
Net profit margin %18.29.0 202.4%  
BALANCE SHEET DATA
Current assets Rs m48,228117,038 41.2%   
Current liabilities Rs m30,37643,931 69.1%   
Net working cap to sales %32.443.8 73.9%  
Current ratio x1.62.7 59.6%  
Inventory Days Days6896 71.3%  
Debtors Days Days8685 100.5%  
Net fixed assets Rs m64,130107,424 59.7%   
Share capital Rs m3,0001,613 186.0%   
"Free" reserves Rs m57,980156,018 37.2%   
Net worth Rs m60,980157,630 38.7%   
Long term debt Rs m15,76623,693 66.5%   
Total assets Rs m121,924236,626 51.5%  
Interest coverage x18.112.0 150.6%   
Debt to equity ratio x0.30.2 172.0%  
Sales to assets ratio x0.50.7 64.1%   
Return on assets %8.87.2 122.8%  
Return on equity %16.49.5 172.8%  
Return on capital %16.812.8 130.5%  
Exports to sales %28.133.0 85.1%   
Imports to sales %18.90-   
Exports (fob) Rs m15,50655,175 28.1%   
Imports (cif) Rs m10,399NA-   
Fx inflow Rs m15,50656,036 27.7%   
Fx outflow Rs m10,3996,764 153.7%   
Net fx Rs m5,10749,272 10.4%   
CASH FLOW
From Operations Rs m11,54630,685 37.6%  
From Investments Rs m-7,1381,040 -686.1%  
From Financial Activity Rs m-2,417-29,488 8.2%  
Net Cashflow Rs m2,1032,340 89.9%  

Share Holding

Indian Promoters % 40.4 16.0 252.5%  
Foreign collaborators % 20.6 20.8 99.0%  
Indian inst/Mut Fund % 8.4 12.2 68.9%  
FIIs % 10.7 23.7 45.1%  
ADR/GDR % 0.0 1.1 -  
Free float % 19.9 26.2 76.0%  
Shareholders   109,995 161,166 68.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   WOCKHARDT  J.B.CHEMICALS  ORCHID PHARMA  DIVIS LABORATORIES  FULFORD INDIA  

Compare BIOCON With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 272 Points Higher; Hindalco, Hero MotoCorp & Wipro Surge Over 4%(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended higher.

Related Views on News

CIPLA Announces Quarterly Results (3QFY21); Net Profit Up 112.8% (Quarterly Result Update)

Feb 1, 2021 | Updated on Feb 1, 2021

For the quarter ended December 2020, CIPLA has posted a net profit of Rs 8 bn (up 112.8% YoY). Sales on the other hand came in at Rs 52 bn (up 18.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

BIOCON Announces Quarterly Results (3QFY21); Net Profit Down 19.7% (Quarterly Result Update)

Jan 25, 2021 | Updated on Jan 25, 2021

For the quarter ended December 2020, BIOCON has posted a net profit of Rs 2 bn (down 19.7% YoY). Sales on the other hand came in at Rs 19 bn (up 5.9% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

CIPLA 2019-20 Annual Report Analysis (Annual Result Update)

Nov 4, 2020 | Updated on Nov 4, 2020

Here's an analysis of the annual report of CIPLA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

BIOCON Announces Quarterly Results (2QFY21); Net Profit Down 23.9% (Quarterly Result Update)

Oct 29, 2020 | Updated on Oct 29, 2020

For the quarter ended September 2020, BIOCON has posted a net profit of Rs 2 bn (down 23.9% YoY). Sales on the other hand came in at Rs 17 bn (up 11.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

CIPLA Announces Quarterly Results (1QFY21); Net Profit Up 21.4% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, CIPLA has posted a net profit of Rs 6 bn (up 21.4% YoY). Sales on the other hand came in at Rs 43 bn (up 7.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

More Views on News

Most Popular

Power Grid's InvIT IPO: Key Points to Consider(Company Info)

Apr 23, 2021

In this article, we discuss the key reasons why the stock of Power Grid was in focus today.

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

This Fund Manager Has Taken the World by Storm. Will You Invest With Her?(Profit Hunter)

Apr 26, 2021

Should you invest with this Rockstar fund manager who has outperformed in a big way?

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


May 6, 2021 (Close)

TRACK BIOCON

COMPARE BIOCON WITH

MARKET STATS